Drug Approval | November 22, 2023
Lupin receives approval from USFDA for Pitavastatin Tablets
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The product will be manufactured at Lupin’s Nagpur facility in India
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
